Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
Abstract The current study evaluated the effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and investigated its possible mechanisms. 124 patients were randomized to receive 25 mg empagliflozin QD, or placebo double bl...
Main Authors: | Lan Cheng, Qianyu Fu, Longhua Zhou, Yuqin Fan, Fenfen Liu, Yuanyuan Fan, Xin Zhang, Weiqing Lin, Xiaohe Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-07395-x |
Similar Items
-
Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
by: Qianyu Fu, et al.
Published: (2023-11-01) -
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
by: Marvin Heimke, et al.
Published: (2022-10-01) -
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
by: Sebastian Steven, et al.
Published: (2017-10-01) -
The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
by: Diana Alegre-González, et al.
Published: (2025-10-01) -
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)